Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies

Shared decision making (SDM) is the process through which patients and their medical provider mutually explore therapy goals, risk/benefit, and treatment options regarding medical care. Decision aids are tools that aid in the process of values clarification and help assess decisional needs and poten...

Full description

Saved in:
Bibliographic Details
Published inAnnals of allergy, asthma, & immunology Vol. 125; no. 1; pp. 90 - 96
Main Authors Greenhawt, Matthew, Shaker, Marcus, Winders, Tonya, Bukstein, Don A., Davis, Ray S., Oppenheimer, John, Fleischer, David M., Kim, Edwin, Chan, Edmond S., Stukus, David R., Matlock, Daniel
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2020
Online AccessGet full text

Cover

Loading…
More Information
Summary:Shared decision making (SDM) is the process through which patients and their medical provider mutually explore therapy goals, risk/benefit, and treatment options regarding medical care. Decision aids are tools that aid in the process of values clarification and help assess decisional needs and potential decisional conflicts. To develop and assess acceptability of a decision aid for commercial peanut allergy therapies. The creation of this decision aid occurred in 3 stages, including a qualitative study to assess decisional needs, development of a draft decision aid through multiple iterations in accordance with international guidelines and decision aid experts, and assessment of decisional acceptability, decisional conflict, and decisional self-efficacy related to using the decision aid. The decision aid went through 9 iterations, resulting in a 4-page aid with 7 parts, explaining the therapies, key risks and benefits of therapy choices, relative importance of key attributes of the therapies, and a self-check assessment regarding informational adequacy and how to take the next steps. A total of 24 subjects assessed the decision aid, noting it had good acceptability, high decisional self-efficacy (mean score 91.9/100), and low decisional conflict (mean score 20.2/100). Respondents rated the information content as adequate and sufficient and the information regarding the therapy choices as fair and balanced without a clear bias or presenting a “best choice.” We have developed this decision aid as a tool to help caregivers navigate the complexity of decision making for peanut allergy treatment options. The decision aid was noted to have good acceptability, with scores reflective of the instrument enhancing decisional self-efficacy and reducing decisional conflict.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1081-1206
1534-4436
1534-4436
DOI:10.1016/j.anai.2020.01.030